Kriya Therapeutics
Clinical-stage biotechnology company developing one-time (durable) gene therapies for prevalent chronic diseases. The organization integrates vector engineering, preclinical and clinical development, analytical sciences, and GMP manufacturing into a single product engine powered by a proprietary, AI-enabled structured data platform to accelerate development and scale manufacturing.
Industries
Nr. of Employees
medium (51-250)
Kriya Therapeutics
Palo Alto, California, United States, North America
Patents
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
US-12071633-B2
View Details
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
US-12071633-B2
View DetailsProducts
One-time gene therapy for Geographic Atrophy (complement inhibition, AAV-based)
A single-administration AAV gene therapy engineered to express a fusion protein that inhibits complement cascade activity at C3/C5 convertase to reduce retinal lesion growth in geographic atrophy.
One-time gene therapy for Thyroid Eye Disease (anti-IGF1R expression, AAV-based)
A single-administration AAV gene therapy designed to express an anti-IGF1R antibody locally in orbital tissues to block IGF1R signaling and reduce inflammation and tissue expansion.
One-time gene therapy for Type 1 Diabetes (glucokinase expression, AAV-based)
AAV gene therapy intended to express glucokinase in skeletal muscle to enable glucose-responsive glucose clearance independent of pancreatic insulin production.
One-time gene therapy for Steatotic Liver Disease (native FGF21 expression, AAV-based)
AAV gene therapy designed to express native human FGF21 systemically to reverse fibrosis and steatosis and improve metabolic profile in steatotic liver disease.
One-time gene therapy for Trigeminal Neuralgia (engineered ion channel, AAV-based)
AAV gene therapy delivering an engineered ion channel to trigeminal nerve tissue; channel activity is designed to be controllable and reversible via an oral small molecule.
KRIYA-839
A potential one-time AAV-based gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable glycemic control and reducing or eliminating the need for exogenous insulin.
One-time gene therapy for Geographic Atrophy (complement inhibition, AAV-based)
A single-administration AAV gene therapy engineered to express a fusion protein that inhibits complement cascade activity at C3/C5 convertase to reduce retinal lesion growth in geographic atrophy.
One-time gene therapy for Thyroid Eye Disease (anti-IGF1R expression, AAV-based)
A single-administration AAV gene therapy designed to express an anti-IGF1R antibody locally in orbital tissues to block IGF1R signaling and reduce inflammation and tissue expansion.
One-time gene therapy for Type 1 Diabetes (glucokinase expression, AAV-based)
AAV gene therapy intended to express glucokinase in skeletal muscle to enable glucose-responsive glucose clearance independent of pancreatic insulin production.
One-time gene therapy for Steatotic Liver Disease (native FGF21 expression, AAV-based)
AAV gene therapy designed to express native human FGF21 systemically to reverse fibrosis and steatosis and improve metabolic profile in steatotic liver disease.
One-time gene therapy for Trigeminal Neuralgia (engineered ion channel, AAV-based)
AAV gene therapy delivering an engineered ion channel to trigeminal nerve tissue; channel activity is designed to be controllable and reversible via an oral small molecule.
KRIYA-839
A potential one-time AAV-based gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable glycemic control and reducing or eliminating the need for exogenous insulin.
Expertise Areas
- Gene therapy development
- AAV vector engineering and plasmid design
- GMP biomanufacturing and scale-up
- Process development (upstream and downstream)
Key Technologies
- AAV viral vector gene delivery
- Plasmid and vector genome design
- Bioreactor-based bioprocessing (50 L–3,000 L)
- Automated aseptic fill–finish systems
News & Updates
Preclinical study reporting that a single intramuscular administration of an AAV-FGF21 vector extended health span and lifespan and produced sustained multi-organ benefits in aged mice; supports development of native FGF21 gene therapy candidate for steatotic liver disease.
Selection by the U.S. Food and Drug Administration PreCheck Pilot Program in recognition of integrated manufacturing infrastructure and commercial manufacturing readiness.
Selected to participate in FDA PreCheck Pilot Program reflecting investment in modern manufacturing technologies and facility readiness.
Preclinical study reporting that a single intramuscular administration of an AAV-FGF21 vector extended health span and lifespan and produced sustained multi-organ benefits in aged mice; supports development of native FGF21 gene therapy candidate for steatotic liver disease.
Selection by the U.S. Food and Drug Administration PreCheck Pilot Program in recognition of integrated manufacturing infrastructure and commercial manufacturing readiness.
Selected to participate in FDA PreCheck Pilot Program reflecting investment in modern manufacturing technologies and facility readiness.